Merck and Moderna release early phase 3 melanoma vaccine data showing primary endpoint success but weaker secondary results

Merck and Moderna disclosed phase 3 data for their melanoma vaccine INTerpath-001 ahead of schedule after an embargo breach.

The trial met its primary endpoint of recurrence‑free survival, with results close to analysts’ best‑case expectations, prompting a share rally earlier.

However, a key secondary endpoint fell short of expectations, tempering enthusiasm about the overall benefit.

The companies released the data before the planned ESMO Congress presentation to address the leak, and the detailed numbers will be discussed at the meeting.